Information  X 
Enter a valid email address

Glaxosmithkline PLC Ord 25P (GSK)

Date Time Source Announcement
17 Oct 2018 5:56 pm
RNS
Director/PDMR Shareholding
  5:50 pm
RNS
Director/PDMR Shareholding
  11:30 am
RNS
Director/PDMR Shareholding
16 Oct 2018 4:53 pm
RNS
Director/PDMR Shareholding
  9:30 am
RNS
Director/PDMR Shareholding
  9:30 am
RNS
Director/PDMR Shareholding
10 Oct 2018 3:30 pm
RNS
Director/PDMR Shareholding
01 Oct 2018 1:58 pm
RNS
Total Voting Rights
27 Sep 2018 4:35 pm
RNS
Director/PDMR Shareholding
21 Sep 2018 12:30 pm
RNS
CHMP recommends expansion of Trelegy COPD label
14 Sep 2018 9:00 am
RNS
ViiV submits HIV 2DR regulatory application to EMA
12 Sep 2018 5:43 pm
RNS
Director/PDMR Shareholding
10 Sep 2018 8:00 am
RNS
New analysis on efficacy of anti-IL5 biologics SEA
  7:00 am
RNS
GSK receives CRL from FDA for mepolizumab in COPD
07 Sep 2018 2:24 pm
RNS
Director/PDMR Shareholding
  2:18 pm
RNS
Director/PDMR Shareholding
03 Sep 2018 5:00 pm
RNS
Total Voting Rights
30 Aug 2018 5:12 pm
RNS
GSK publishes Q4 2018 Dividend Dates
  8:12 am
RNS
EU approve Nucala in severe asthma in children
24 Aug 2018 10:16 am
RNS
Director/PDMR Shareholding
15 Aug 2018 7:00 am
RNS
Positive headline results for ViiV HC ATLAS study
10 Aug 2018 3:00 pm
RNS
Director/PDMR Shareholding
08 Aug 2018 12:35 pm
RNS
Director/PDMR Shareholding
07 Aug 2018 7:00 am
RNS
Iain Mackay appointed GSK Chief Financial Officer
02 Aug 2018 5:07 pm
RNS
Publication of Base Prospectus
  5:07 pm
RNS
Publication of Base Prospectus
  11:04 am
RNS
Total Voting Rights
31 Jul 2018 5:03 pm
RNS
Director/PDMR Shareholding
  4:37 pm
RNS
Director/PDMR Shareholding
27 Jul 2018 4:30 pm
RNS
Director/PDMR Shareholding
  2:47 pm
RNS
CHMP recommend Nucala for severe asthma children
26 Jul 2018 7:00 am
RNS
GSK reports on FDA Ad Com on mepolizumab for COPD
25 Jul 2018 4:15 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
GSK and 23andMe Agreement
  11:00 am
RNS
2nd Quarter Results
24 Jul 2018 9:01 am
RNS
ViiV announces Juluca 100 week data at AIDS 2018
  9:00 am
RNS
ViiV shows positive phIII data on two-drug combo
19 Jul 2018 4:45 pm
RNS
Director/PDMR Shareholding
17 Jul 2018 5:46 pm
RNS
Director/PDMR Shareholding
  4:54 pm
RNS
Director/PDMR Shareholding
  4:49 pm
RNS
Director/PDMR Shareholding
16 Jul 2018 2:51 pm
RNS
Director/PDMR Shareholding
  11:11 am
RNS
Director/PDMR Shareholding
13 Jul 2018 4:16 pm
RNS
Director/PDMR Shareholding
  4:16 pm
RNS
Director/PDMR Shareholding
11 Jul 2018 2:42 pm
RNS
Director/PDMR Shareholding
02 Jul 2018 2:30 pm
RNS
Total Voting Rights
14 Jun 2018 7:00 am
RNS
Positive headline results for ViiV GEMINI studies
12 Jun 2018 5:15 pm
RNS
Director/PDMR Shareholding
  2:00 pm
RNS
GSK announces changes to Corporate Executive Team
01 Jun 2018 1:00 pm
RNS
GSK completes Consumer Healthcare buyout
  9:42 am
RNS
Total Voting Rights
29 May 2018 7:00 am
RNS
GSK Once-daily single inhaler triple therapy COPD
21 May 2018 11:02 am
RNS
ViiV granted EU marketing authorisation for Juluca
15 May 2018 1:39 pm
RNS
Director/PDMR Shareholding
11 May 2018 3:17 pm
RNS
Director/PDMR Shareholding
10 May 2018 5:20 pm
RNS
Block listing Interim Review
09 May 2018 5:05 pm
RNS
Director/PDMR Shareholding - replacement
  12:00 pm
RNS
Directorate Change
03 May 2018 6:31 pm
RNS
Result of General Meeting
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t